前列腺特异性膜抗原（PSMA）是一种膜结合金属肽酶，在包括神经胶质瘤在内的许多实体瘤的新血管系统中高度表达。由于其内化能力，从而将放射性配体或药物递送至细胞内隔室，因此它是一个特别诱人的治疗靶点。使用 PSMA 来靶向神经胶质瘤的新血管系统进行诊断和管理已成为最近研究和前景不断增加的领域。本综述的目的是综合 PSMA 在神经胶质瘤的组织病理学研究、成像和治疗中的应用现状和未来方向。2023 年 6 月，使用 PubMed 和 Scopus 数据库对 PSMA 在神经胶质瘤中的应用进行了文献综述。检索的内容包括“PSMA”、“前列腺特异性膜抗原”或“PSMA”或“PSMA PET”和“神经胶质瘤”或“高级别神经胶质瘤”或“胶质母细胞瘤”或“GBM”。筛选了 94 篇出版物的相关性正在阅读 61 项研究、病例报告和评论，为 PSMA 在神经胶质瘤管理中的历史、当代和前瞻性应用提供全面的背景。PSMA PET 成像目前是一种用于诊断和管理神经胶质瘤的有前途且准确的放射线照相工具。 PSMA 组织病理学可能是帮助预测神经胶质瘤行为的可行工具。需要更多的研究来调查 PSMA 靶向疗法在神经胶质瘤治疗中的作用，但初步报告已表明其在治疗中的潜在用途。版权所有 © 2024 Wolters Kluwer Health, Inc. 保留所有权利。

Prostate-specific membrane antigen (PSMA) is a membrane-bound metallopeptidase highly expressed in the neovasculature of many solid tumors including gliomas. It is a particularly enticing therapeutic target due to its ability to internalize, thereby delivering radioligands or pharmaceuticals to the intracellular compartment. Targeting the neovasculature of gliomas using PSMA for diagnosis and management has been a recent area of increased study and promise. The purpose of this review is to synthesize the current state and future directions of PSMA use in the histopathologic study, imaging, and treatment of gliomas.PubMed and Scopus databases were used to conduct a literature review on PSMA use in gliomas in June 2023. Terms searched included "PSMA," "Prostate-Specific Membrane Antigen" OR "PSMA" OR "PSMA PET" AND "glioma" OR "high grade glioma" OR "glioblastoma" OR "GBM."Ninety-four publications were screened for relevance with 61 studies, case reports, and reviews being read to provide comprehensive context for the historical, contemporary, and prospective use of PSMA in glioma management.PSMA PET imaging is currently a promising and accurate radiographic tool for the diagnosis and management of gliomas. PSMA histopathology likely represents a viable tool for helping predict glioma behavior. More studies are needed to investigate the role of PSMA-targeted therapeutics in glioma management, but preliminary reports have indicated its potential usefulness in treatment.Copyright © 2024 Wolters Kluwer Health, Inc. All rights reserved.